Evidence map›Paper›PMID 31575704›Full record

Observational studyThe Journal of rheumatology2020

Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease.

Jessica A Walsh, Marilyn T Wan, Christine Willinger, M Elaine Husni, Jose U Scher, Soumya M Reddy, Alexis Ogdie

Open access · bronzeAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The Journal of rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Measuring Outcomes in Psoriatic Arthritis.Arthritis care & research · 2020
    Review
  14. Review
  15. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Jessica A WalshJ.A. Walsh, MD, MBA, A. Ogdie, MD, MSCE, Division of Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia.ORCID 0000-0002-4563-0845
Marilyn T WanM.T. Wan, MBChB, MPH, Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Christine WillingerC. Willinger, BS, University of Pennsylvania, Philadelphia, Pennsylvania.
M Elaine HusniM.E. Husni, MD, MPH, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0002-3181-4205
Jose U ScherJ.U. Scher, MD, S.M. Reddy MD, New York University School of Medicine, New York, New York, USA.ORCID 0000-0002-1072-6994
Soumya M ReddyJ.U. Scher, MD, S.M. Reddy MD, New York University School of Medicine, New York, New York, USA.
Alexis OgdieJ.A. Walsh, MD, MBA, A. Ogdie, MD, MSCE, Division of Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia; alexis.ogdie@uphs.upenn.edu.ORCID 0000-0002-4639-0775
New York University · USUniversity of Pennsylvania · USWalsh University · USCleveland Clinic · US

Funding

Refining Outcome Measurement in Psoriatic Arthritis: Preparation for Pragmatic TrialsR01AR072363 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI OGDIE, ALEXIS R. · 2017 to 2019
$709k
NIAMS NIH HHS R01 AR072363
6 · The paper itself

Abstract

objectiveTo examine the construct validity of Routine Assessment of Patient Index Data 3 (RAPID3) and Psoriatic Arthritis Impact of Disease (PsAID) in patients with psoriatic arthritis (PsA). In examining construct validity, we also addressed scores among subgroups with severe psoriasis, poly articular disease, enthesitis, and dactylitis, and evaluated influences of sociodemographic factors and comorbidities (contextual factors) on these patient-reported outcomes (PRO).

methodsPatients with PsA were enrolled in the Psoriatic Arthritis Research Consortium (PARC) between 2014 and 2016. PARC is a longitudinal observational cohort study conducted at 4 US institutions. In this cross-sectional study, construct validity was assessed by examining Spearman correlation coefficients for RAPID3 and PsAID with physician-reported disease activity measures and other PRO [e.g., Medical Outcomes Study Short Form-12 physical component summary/mental component summary (SF-12 PCS/MCS), Functional Assessment of Chronic Illness Therapy-Fatigue scale (FACIT-F)]. Contextual factors and disease subgroups were assessed in multivariable linear regression models with RAPID3 or PsAID12 as outcomes of interest and the hypothesized contextual factors as covariates.

resultsAmong 401 patients enrolled in PARC, 347 completed RAPID3 or PsAID12. Of these, most were white females with a mean age of 51.7 years (SD 14.02). RAPID3 and PsAID were highly correlated (r = 0.90). These measures were also correlated with the SF-12 PCS (r = -0.67) and FACIT-F (r = -0.77). Important contextual factors and disease subgroups included enthesitis, joint counts, education, insurance type, and depression.

conclusionRAPID3 and PsAID12 have excellent construct validity in PsA and are strongly correlated despite differing items. Contextual factors (i.e., the presence of depression and obesity) should be considered when interpreting raw scores of the RAPID3 and PsAID12.

Indexed as

Arthritis, PsoriaticPsoriasisCross-Sectional StudiesFemaleHumansMiddle AgedOutcome Assessment, Health CareSeverity of Illness Indexpatient-reported outcomespsoriatic arthritis

Identifiers

PMID31575704
PMCPMC11110026
OpenAlexW2978834785

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.